查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010045

生物製藥市場：2026-2032年全球市場預測（依治療領域、技術、產品類型、給藥途徑及通路分類）

Biopharmaceuticals Market by Therapeutic Area, Technology, Product Type, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年生物製藥市場價值為6,900.4億美元，預計到2026年將成長至7,493.3億美元，複合年成長率為10.10%，到2032年將達到1,3536.4億美元。

主要市場統計數據
基準年 2025 6900.4億美元
預計年份：2026年 7493.3億美元
預測年份 2032 13536.4億美元
複合年成長率 (%) 10.10%

權威說明指出，科學突破、監管複雜性和商業性需求正在重塑整個生物製藥產業的戰略重點。

生物製藥產業正進入一個技術快速成熟和策略重組的階段，這主要得益於生物製藥、基因療法以及利用數位技術的患者照護模式的進步。相關人員正在適應一個科學突破與日益嚴格的監管審查、複雜的供應鏈以及不斷變化的支付方期望相互交織的環境。為此，經營團隊正在重新評估其業務組合，投資於生產靈活性，並在學術界、合約研發生產機構（CDMO）和數位醫療服務提供者之間建立新的合作夥伴關係。

本文概述了科學、製造和監管預期方面最重大的變化，這些變化正在重新定義生物製藥領域的競爭優勢和策略性投資。

該產業正經歷變革性的轉變，重塑著藥物發現、開發和供應各個階段的競爭優勢。首先，治療方法的多樣化正在加速。細胞和基因療法正從實驗階段邁向商業化階段，而重組技術和融合瘤方法也在不斷改進，製程最佳化和分析技術不斷進步。同時，數位化工具和真實世界數據正日益融入研發和打入市場策略，從而能夠採用適應性試驗設計，並更有效率地產生核准後證據。

分析檢視 2025 年關稅調整對生物製程原料和成品生物製藥產品的影響將如何改變籌資策略、供應彈性和商業合約。

2025年即將推出的關稅和貿易措施等政策將影響生物製藥原料和成品，對擁有跨境供應鏈的企業帶來新的營運壓力。原料、一次性耗材和某些生物製程設備的進口關稅提高，推高了依賴全球採購的企業的生產成本，促使它們尋求供應商多元化並重新審視在地採購策略。因此，企業正在迅速開展供應商風險評估，並優先選擇替代供應商以降低供應中斷的風險。

將治療重點、技術平台、通路和給藥途徑與策略開發和商業化方案聯繫起來的全面細分洞察。

詳細的細分洞察揭示了治療重點如何與技術選擇、分銷偏好和產品類型相契合，從而塑造差異化的開發和市場策略。依治療領域分類，治療方法範圍涵蓋自體免疫疾病（如發炎性腸道疾病、乾癬和類風濕性關節炎） ；心血管疾病（包括心臟衰竭、高膽固醇症和高血壓）；感染疾病（涵蓋抗生素、抗病毒藥物和疫苗）；神經病學（重點阿茲海默症、骨髓惡性腫瘤和囊腫纖維化氏症（固體癌學（腫瘤學）。每個臨床重點領域都決定了不同的臨床開發路徑和核准後證據要求。

重點區域觀察結果，強調美洲、歐洲、中東和非洲以及亞太地區的法規結構、支付系統和物流如何影響戰略規劃。

區域趨勢影響監管預期、支付系統和營運物流，進而對策略規劃和實施產生重大影響。在美洲，市場准入途徑是與集中式支付方和區域報銷政策進行談判的綜合體現，這需要量身定做的衛生經濟學證據和彈性價格設定策略。從供應鏈角度來看，穩健的低溫運輸物流和跨境分銷緊急時應對計畫至關重要，而分散式臨床試驗模式也日益受到關注，以提高病患招募和留存率。

關鍵的企業級洞察突顯了整合能力、夥伴關係和跨職能人才投資如何創造競爭優勢。

企業層面的舉措，尤其是著重於差異化能力、策略夥伴關係和卓越營運的舉措，持續塑造競爭動態。主要企業正在整合其在先進生物製藥和基因療法製造方面的核心能力，同時將一些細分領域的業務外包給專業的合約合作夥伴。此外，他們也正在投資建置數位化平台，整合臨床、生產和商業數據，以加快決策速度，並提升產品全生命週期的可追溯性。

為行業領導者提供可操作的建議，優先考慮產品組合重點、製造敏捷性和商業化準備，以將科學創新轉化為永續的競爭優勢。

領導企業必須採取果斷行動，迅速將研發誠信、生產柔軟性和商業性韌性等領域的洞察轉化為實際行動。首先，應優先精簡產品組合，將投資集中在具有明確臨床差異和可行監管路徑的適應症和治療方法。將藥物研發重點與可擴展的生產方式結合，將降低下游風險，並實現更可預測的供應計畫。同時，應透過認證雙源供應商、投資模組化生產設施以及採用可處理多個產品系列的平台技術，來提升生產柔軟性。

我們透明且可重複的調查方法，結合了與關鍵相關人員的訪談、監管審查和情境分析，得出可操作的營運和策略見解。

為確保可靠性和透明度，本分析採用結構化且可重複的調查方法，整合了來自一手和二手研究的發現。一手資料包括對生物製藥研發、生產、監管事務和商業部門的高級管理人員以及負責人的定性訪談。二手資料包括監管指導文件、臨床和科學文獻、行業政策公告以及支持主題趨勢和營運影響的上市公司披露資訊。

簡潔的結論強調了為什麼涵蓋科學、製造和取得的整合策略對於將治療方法創新轉化為永續的患者和商業性成果至關重要。

總之，生物製藥產業正處於轉折點，科學進步、製造創新和政策趨勢在此交匯，既帶來機會也帶來風險。能夠整合跨部門策略，將治療方法優先順序與合適的技術平台、穩健的供應鏈以及符合實際情況的商業模式相結合的機構，將獲得最大的長期價值。同樣重要的是，需要事先規劃，以應對外部壓力，例如貿易政策調整和區域監管差異，這些因素可能對產品供應和價格趨勢產生重大影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物製藥市場：依治療領域分類

  • 自體免疫
    • 發炎性腸道疾病
    • 銀屑病
    • 類風濕性關節炎
  • 循環系統
    • 心臟衰竭
    • 高膽固醇症
    • 高血壓
  • 感染疾病
    • 抗生素
    • 抗病毒藥物
    • 疫苗
  • 神經病學
    • 阿茲海默症
    • 多發性硬化症
    • 帕金森氏症
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌
  • 罕見疾病
    • 囊腫纖維化
    • 血友病
    • 溶小體貯積症

第9章：生物製藥市場：依技術分類

  • 細胞培養
    • 哺乳動物
    • 微生物
  • 基因治療
    • 非病毒載體
    • 病毒載體
  • 融合瘤
  • 重組DNA

第10章：生物製藥市場：依產品類型分類

  • 生物相似藥
  • 學名藥

第11章：生物製藥市場：依給藥途徑分類

  • 吸入
  • 肌肉內部
  • 靜脈
  • 口服
  • 皮下
  • 外用

第12章 生物製藥市場：依通路分類

  • 離線
  • 線上

第13章 生物製藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 生物製藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 生物製藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國生物製藥市場

第17章：中國生物製藥市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CSL Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Kyowa Kirin Co. Ltd.
  • Merck & Co. Inc.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
Product Code: MRR-434CCDA05130

The Biopharmaceuticals Market was valued at USD 690.04 billion in 2025 and is projected to grow to USD 749.33 billion in 2026, with a CAGR of 10.10%, reaching USD 1,353.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 690.04 billion
Estimated Year [2026] USD 749.33 billion
Forecast Year [2032] USD 1,353.64 billion
CAGR (%) 10.10%

An authoritative introduction to how scientific breakthroughs, regulatory complexity, and commercial demands are reshaping strategic priorities across the biopharmaceutical sector

The biopharmaceutical landscape has entered a phase of rapid technological maturation and strategic repositioning, driven by advances in biologics, gene therapies, and digital-enabled patient care models. Industry stakeholders are adapting to an environment where scientific breakthroughs meet heightened regulatory scrutiny, complex supply chains, and evolving payer expectations. In response, executives are reevaluating portfolios, investing in manufacturing agility, and forging new collaborations that span academia, contract development and manufacturing, and digital health providers.

Consequently, organizations must balance scientific ambition with operational resilience. Firms that align R&D priorities with scalable manufacturing technologies and that integrate patient-centric distribution channels are better positioned to convert innovation into sustained clinical and commercial impact. From an investor and leadership perspective, the imperative is clear: translate complex scientific advances into reproducible processes, credible regulatory strategies, and robust commercialization plans that reduce time to patient.

A synthesis of the most consequential shifts in science, manufacturing, and regulatory expectations that are redefining competitive advantage and strategic investment in biopharmaceuticals

The sector is experiencing transformative shifts that reconfigure competitive advantages across discovery, development, and delivery. First, modality diversification has accelerated; cell and gene therapies are transitioning from experimental to commercial stages, while recombinant and hybridoma approaches continue to evolve with process optimizations and analytical improvements. At the same time, digital tools and real-world evidence are increasingly integrated into development and market access strategies, enabling adaptive trial designs and more efficient post-approval evidence generation.

Moreover, supply chain resilience and manufacturing agility have moved from operational objectives to strategic imperatives. Companies are investing in flexible cell culture platforms and modular facilities, and they are pursuing decentralized distribution pathways to bring therapies closer to patients. Regulatory frameworks are also adapting, with agencies issuing guidance that supports expedited pathways while demanding rigorous long-term safety monitoring. These combined dynamics call for cross-functional alignment, where R&D, regulatory, manufacturing, and commercial teams converge on shared milestones and risk management approaches.

An analytical review of how 2025 tariff adjustments affecting bioprocessing inputs and finished biologics are altering sourcing strategies, supply resilience, and commercial contracts

Policy actions in 2025 introducing tariffs and trade measures affecting biologics inputs and finished products have introduced new operational pressures for firms with cross-border supply chains. Increased import duties on raw materials, single-use consumables, and certain bioprocessing equipment raise production costs for organizations that rely on globalized procurement, prompting a reassessment of supplier diversification and local sourcing strategies. In turn, companies are conducting rapid supplier risk assessments and prioritizing qualification of alternative vendors to mitigate interruptions.

These tariff-related pressures also influence commercial strategies. Firms evaluating route-to-market decisions face higher landed costs in affected geographies, which can alter pricing negotiations with payers and distributors. As a result, organizations are exploring contractual hedges, localized manufacturing partnerships, and value-based contracting to preserve access and margins. From a strategic perspective, these developments accelerate the shift toward nearshoring and regional manufacturing capacity while emphasizing inventory optimization and scenario planning to preserve continuity of clinical supply and commercial distribution.

Comprehensive segmentation-driven insights that link therapeutic priorities, technology platforms, distribution pathways, and administration routes to strategic development and commercialization choices

Deep segmentation insight reveals where therapeutic priorities align with technology choices, distribution preferences, and product types, shaping differentiated development and go-to-market strategies. When therapies are organized by therapeutic area, the landscape spans autoimmune conditions including inflammatory bowel disease, psoriasis, and rheumatoid arthritis; cardiovascular indications that encompass heart failure, hypercholesterolemia, and hypertension; infectious disease categories covering antibiotics, antivirals, and vaccines; neurology areas focused on Alzheimer's disease, multiple sclerosis, and Parkinson's disease; oncology workstreams addressing hematological malignancies and solid tumors; and rare disease programs targeting cystic fibrosis, hemophilia, and lysosomal storage disorders. These clinical focuses drive distinct clinical development pathways and post-approval evidence needs.

Concurrently, technology segmentation maps onto those clinical priorities. Cell culture platforms, subdivided into mammalian and microbial systems, remain essential for many recombinant biologics, while gene therapy approaches split between viral and nonviral vectors demand specialized manufacturing know-how and long-term safety monitoring. Hybridoma and recombinant DNA techniques continue to underpin monoclonal antibody development and biosimilar production. Distribution channel segmentation differentiates direct-to-patient models and hospital pharmacy fulfillment from online and retail pharmacy pathways, each requiring tailored cold chain, adherence support, and reimbursement navigation. Product type divides into biosimilars and generics, which impose distinct regulatory and commercialization tactics. Route of administration choices-ranging from inhalation and intramuscular to intravenous, oral, subcutaneous, and topical-further inform formulation development, patient adherence programs, and supply logistics. Finally, direct sales, hospital pharmacies, online pharmacies, and retail pharmacies represent overlapping but distinct distribution networks that influence commercial resource allocation and channel-specific patient engagement strategies.

Taken together, these segmentation layers enable more precise portfolio management. By aligning therapeutic ambitions with appropriate technology platforms, distribution routes, and product types, organizations can define clearer clinical development hypotheses, optimize manufacturing investments, and tailor commercialization plans that address payer expectations and patient access dynamics.

Key regional observations highlighting how regulatory frameworks, payer systems, and logistics across the Americas, Europe Middle East & Africa, and Asia-Pacific influence strategic planning

Regional dynamics shape regulatory expectations, payer systems, and operational logistics in ways that materially affect strategic planning and execution. In the Americas, market access pathways are shaped by a mix of centralized payer negotiation and regional reimbursement policies, which requires tailored health economics evidence and flexible pricing approaches. Supply chain considerations emphasize robust cold chain logistics and contingency planning for cross-border distribution, while decentralized clinical trial models are gaining traction to enhance patient recruitment and retention.

In Europe, Middle East & Africa, regulatory harmonization initiatives coexist with heterogeneous reimbursement landscapes, calling for differentiated strategies that incorporate local health technology assessment requirements and region-specific safety monitoring obligations. Companies often adopt phased market entry plans and regionally adapted value dossiers. Meanwhile, the Asia-Pacific region presents a diverse mix of regulatory maturity, manufacturing capability, and rapidly evolving patient access frameworks. Here, partnering with regional contract manufacturers and leveraging local clinical infrastructure can accelerate access, while market-specific pricing and reimbursement strategies remain essential. Across all regions, geopolitical shifts, trade policy, and infrastructure capability interact to influence where companies prioritize manufacturing investment, clinical programs, and commercial launches.

Critical company-level insights emphasizing how capability consolidation, partnerships, and cross-functional talent investments are shaping competitive differentiation

Company-level behavior continues to define competitive dynamics, with an emphasis on differentiated capabilities, strategic partnerships, and operational excellence. Leading organizations are consolidating core capabilities in advanced biologics and gene therapy manufacturing while outsourcing niche activities to specialized contract partners. They are also investing in digital platforms that integrate clinical, manufacturing, and commercial data to accelerate decision-making and improve traceability across product lifecycles.

Strategic alliances and licensing arrangements remain central to expanding pipelines and accessing new geographies. Companies with robust in-house regulatory expertise are better positioned to navigate adaptive approval pathways and to design post-approval evidence programs that support market access. Additionally, there is heightened attention to talent acquisition in bioprocess engineering, regulatory science, and value access functions. Firms that cultivate cross-disciplinary teams can move more efficiently from innovation to scale, reducing operational friction and increasing the likelihood of sustained commercial success.

Actionable recommendations for industry leaders that prioritize portfolio focus, manufacturing agility, and commercial readiness to translate scientific innovation into durable competitive advantage

Leaders must move decisively to convert insight into action across R&D alignment, manufacturing flexibility, and commercial resilience. First, prioritize portfolio rationalization that focuses investments on indications and modalities with clear clinical differentiation and feasible regulatory pathways. Aligning discovery priorities with scalable manufacturing approaches reduces downstream risk and facilitates more predictable supply planning. At the same time, expand manufacturing flexibility by qualifying dual-source suppliers, investing in modular production assets, and adopting platform technologies that can accommodate multiple product families.

Second, strengthen commercial readiness by developing distribution models that match therapy characteristics and patient needs. For therapies requiring specialized handling or administration, design provider engagement programs and patient-support infrastructure that reduce barriers to adoption. Negotiate payer arrangements that leverage robust real-world evidence and value-based contracting to support access. Third, accelerate strategic partnerships with academic centers, contract manufacturers, and digital-health providers to access technical expertise and local market knowledge. Finally, institutionalize scenario-based planning that incorporates policy shifts such as tariffs and trade restrictions so organizations can pivot rapidly while preserving clinical supply and payer relationships.

A transparent and reproducible research methodology combining primary stakeholder interviews, regulatory review, and scenario analysis to derive actionable operational and strategic insights

This analysis synthesizes primary and secondary research inputs with a structured, reproducible methodology to ensure credibility and transparency. Primary inputs include qualitative interviews conducted with senior executives across biopharma research and development, manufacturing, regulatory affairs, and commercial operations, as well as practitioners from contract development and manufacturing organizations and distribution partners. Secondary sources include regulatory guidance documents, clinical and scientific literature, industry policy releases, and public company disclosures that validate thematic trends and operational implications.

Analysts applied a layered approach to data synthesis, combining thematic coding of qualitative interviews with comparative analysis of regulatory and operational frameworks across regions. Scenario analysis was used to evaluate the operational impact of trade policy shifts and supply chain disruptions, and triangulation across multiple sources ensured robustness of the insights. Throughout the process, emphasis was placed on identifying actionable implications rather than producing quantitative estimates, and gaps in public information were noted to guide potential follow-up inquiries and customized client engagements.

A concise conclusion emphasizing why integrated strategies across science, manufacturing, and access are essential to convert therapeutic innovation into sustained patient and commercial outcomes

In conclusion, the biopharmaceutical sector stands at an inflection point where scientific advances, manufacturing innovation, and policy dynamics converge to create both opportunity and risk. Organizations that integrate cross-functional strategies-linking therapeutic prioritization with appropriate technology platforms, resilient supply chains, and context-sensitive commercial models-will capture the greatest long-term value. Equally important is the need to anticipate and plan for external pressures such as trade policy adjustments and regional regulatory divergence, which can materially affect product availability and pricing dynamics.

Therefore, executive teams should commit to deliberate investments in flexible manufacturing, strategic partnerships, and evidence-generation capabilities that support access negotiations. By aligning organizational capabilities with the nuanced requirements of different therapeutic areas, routes of administration, and distribution channels, companies can convert scientific promise into sustainable patient impact and commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopharmaceuticals Market, by Therapeutic Area

  • 8.1. Autoimmune
    • 8.1.1. Inflammatory Bowel Disease
    • 8.1.2. Psoriasis
    • 8.1.3. Rheumatoid Arthritis
  • 8.2. Cardiovascular
    • 8.2.1. Heart Failure
    • 8.2.2. Hypercholesterolemia
    • 8.2.3. Hypertension
  • 8.3. Infectious Disease
    • 8.3.1. Antibiotics
    • 8.3.2. Antivirals
    • 8.3.3. Vaccines
  • 8.4. Neurology
    • 8.4.1. Alzheimers
    • 8.4.2. Multiple Sclerosis
    • 8.4.3. Parkinsons
  • 8.5. Oncology
    • 8.5.1. Hematological Malignancies
    • 8.5.2. Solid Tumors
  • 8.6. Rare Disease
    • 8.6.1. Cystic Fibrosis
    • 8.6.2. Hemophilia
    • 8.6.3. Lysosomal Storage Disorders

9. Biopharmaceuticals Market, by Technology

  • 9.1. Cell Culture
    • 9.1.1. Mammalian
    • 9.1.2. Microbial
  • 9.2. Gene Therapy
    • 9.2.1. Nonviral Vector
    • 9.2.2. Viral Vector
  • 9.3. Hybridoma
  • 9.4. Recombinant Dna

10. Biopharmaceuticals Market, by Product Type

  • 10.1. Biosimilars
  • 10.2. Generics

11. Biopharmaceuticals Market, by Route Of Administration

  • 11.1. Inhalation
  • 11.2. Intramuscular
  • 11.3. Intravenous
  • 11.4. Oral
  • 11.5. Subcutaneous
  • 11.6. Topical

12. Biopharmaceuticals Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Biopharmaceuticals Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopharmaceuticals Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopharmaceuticals Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biopharmaceuticals Market

17. China Biopharmaceuticals Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Biogen Inc.
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. CSL Limited
  • 18.12. Dr. Reddy's Laboratories Ltd.
  • 18.13. Eli Lilly and Company
  • 18.14. Gilead Sciences Inc.
  • 18.15. GlaxoSmithKline plc
  • 18.16. Intas Pharmaceuticals Ltd.
  • 18.17. Johnson & Johnson
  • 18.18. Kyowa Kirin Co. Ltd.
  • 18.19. Merck & Co. Inc.
  • 18.20. Novartis International AG
  • 18.21. Novo Nordisk A/S
  • 18.22. Pfizer Inc.
  • 18.23. Roche Holding AG
  • 18.24. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PARKINSONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PARKINSONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PARKINSONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMOPHILIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMOPHILIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MAMMALIAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NONVIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NONVIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NONVIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYBRIDOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYBRIDOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYBRIDOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. GCC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. GCC BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 268. GCC BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 269. GCC BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 270. GCC BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. GCC BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. GCC BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 274. GCC BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 276. GCC BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. GCC BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. GCC BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. GCC BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. G7 BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 309. G7 BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 310. G7 BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 311. G7 BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 312. G7 BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 313. G7 BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. G7 BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. G7 BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 316. G7 BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. G7 BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 318. G7 BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 319. G7 BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. G7 BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. G7 BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. NATO BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 323. NATO BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 324. NATO BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 325. NATO BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 326. NATO BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 327. NATO BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 328. NATO BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. NATO BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 330. NATO BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. NATO BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 332. NATO BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 333. NATO BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. NATO BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. NATO BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 336. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES BIOPHARMACEUTICALS MAR